The DOI matches its Crossref record.
A Low Dose Bacillus Calmette-Guerin Regimen in Superficial Bladder Cancer Therapy: Is it Effective?
Abstract
Bacillus Calmette-Guerin (BCG) intravesical therapy represents a major advance in the treatment of superficial transitional cell carcinoma of the bladder. To date, however, the optimal treatment schedule must be defined and the toxicity related to the treatment is significant. The preliminary results of a randomized ongoing study performed to evaluate the effectiveness and relative toxicity of a low dose (75 mg.) BCG regimen in the treatment of superficial bladder cancer therapy are reported. A total of 126 patients (70 for prophylaxis of recurrent stages Ta and T1 papillary tumors and 56 for treatment of carcinoma in situ or with microinfiltration of the subepithelial connective tissue) underwent a 6-week course of 75 mg. BCG (Pasteur vaccine). An additional course was given in patients who failed to respond to the induction course. Maintenance therapy was administered in complete responders monthly for 1 year and then quarterly for 1 year. The prophylaxis group (transurethral resection plus BCG) was randomized versus transurethral resection alone (63 patients, control group). A complete response in the prophylaxis, control and therapy groups was observed in 74, 17 and 57% of the patients, respectively, while 4, 17 and 12.5%, respectively, experienced tumor progression. The additional course of therapy increased the response rate. On the contrary, previous unsuccessful intravesical chemotherapy did not affect the response rate. In regard to toxicity, irritative disturbances (27%) and fever (17%) appeared to be significantly decreased compared with the rates reported in the literature. No major complications were experienced. In conclusion, a low dose (75 mg.) Pasteur strain BCG regimen was effective as prophylaxis against recurrent superficial papillary tumors and as treatment of carcinoma in situ or with microinfiltration of the subepithelial connective tissue. Toxicity related to the treatment appeared to be low.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
SYLVESTER, R. J., van der MEIJDEN, A. P. M., & LAMM, D. L. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64273-5 · Cited by 1,312
The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year Outcome
Cookson, M. S., Herr, H. W., Zhang, Z.-F., Soloway, S., Sogani, P. C., & Fair, W. R. (1997) · Journal of Urology · doi:10.1097/00005392-199707000-00017 · Cited by 549
Efficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer
Lamm, D. L. (2000) · Clinical Infectious Diseases · doi:10.1086/314064 · Cited by 264
Agrawal, M. S., Agrawal, M., Bansal, S., Agarwal, M., Lavania, P., & Goyal, J. (2007) · Urology · doi:10.1016/j.urology.2007.07.017 · Cited by 44
Metadata
- Authors
- Pagano, F., Bassi, P., Milani, C., Meneghini, A., Maruzzi, D., & Garbeglio, A.
- Venue
- Journal of Urology
- Published
- 1991-07
- Volume
- 146
- Issue
- 1
- Pages
- 32-35
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2406405012
- Cited by
- 170
- References
- 0
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Low Dose Bacillus Calmette-Guerin Regimen in Superficial Bladder Cancer Therapy: Is it Effective? https://app.cochat.ai/papers/10.1016/s0022-5347(17)37707-8
- The paper
- Pagano, F., Bassi, P., Milani, C., Meneghini, A., Maruzzi, D., & Garbeglio, A. (1991). A Low Dose Bacillus Calmette-Guerin Regimen in Superficial Bladder Cancer Therapy: Is it Effective? Journal of Urology. https://doi.org/10.1016/s0022-5347(17)37707-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.